Results 91 to 100 of about 4,312 (239)
Progress in RNA‐Targeted Therapeutics for Human Diseases
RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang +10 more
wiley +1 more source
ADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancers. [PDF]
A growing list of microRNAs (miRNAs) show aberrant expression patterns in hepatocellular carcinoma (HCC), but the regulatory mechanisms largely remain unclear.
Wan-Hsin Liu +7 more
doaj +1 more source
Systematic identification of edited microRNAs in the human brain [PDF]
Adenosine-to-inosine (A-to-I) editing modifies RNA transcripts from their genomic blueprint. A prerequisite for this process is a double-stranded RNA (dsRNA) structure.
Alon, Shahar +8 more
core +1 more source
Increased miR‐3163 targets NUDT21, reducing CPSF5 levels and driving APA dysregulation. This results in 3′UTR shortening of CBFB, which stabilizes RUNX1 and promotes smooth muscle proliferation. PTGER3, is also shortened amplifying hypoxia‐induced RVSP. Together, these pathways contribute to vascular remodeling in PH. Image Created in https://BioRender.
Scott D. Collum +17 more
wiley +1 more source
Adenosine deaminases acting on RNA (ADARs) are endogenous enzymes catalyzing the deamination of adenosines to inosines, which are then read as guanosines during translation. This ability to recode makes ADAR an attractive therapeutic tool to edit genetic
Nina Schneider +9 more
doaj +1 more source
Abnormal expression of an ADAR2 alternative splicing variant in gliomas downregulates adenosine-to-inosine RNA editing [PDF]
BACKGROUND: RNA editing is catalyzed by adenosine deaminases acting on RNA (ADARs). ADAR2 is the main enzyme responsible for recoding editing in humans. Adenosine-to-inosine (A-to-I) editing at the Q/R site is reported to be decreased in gliomas; however,
Bin Qi +11 more
core +1 more source
Genetic Pigmentary Disorders: From Molecular Mechanisms to Clinical Manifestations
ABSTRACT Genetic pigmentary disorders represent a diverse group of genetic conditions characterized by alterations in melanin production and transport and melanocyte development, resulting from single‐gene pathological variants. These disorders encompass both hypopigmentary and hyperpigmentary phenotypes, affecting not only skin pigmentation but also ...
Ken Okamura, Tamio Suzuki
wiley +1 more source
The RNA-Editing Enzyme ADAR1 Controls Innate Immune Responses to RNA
The ADAR RNA-editing enzymes deaminate adenosine bases to inosines in cellular RNAs. Aberrant interferon expression occurs in patients in whom ADAR1 mutations cause Aicardi-Goutières syndrome (AGS) or dystonia arising from striatal neurodegeneration ...
Niamh M. Mannion +16 more
doaj +1 more source
Plasma Proteome Profiling of Centenarian Across Switzerland Reveals Key Youth‐Associated Proteins
We characterized the plasma proteomic profiles of centenarians from the SWISS100 cohort, identifying 583 differentially expressed proteins compared to younger and geriatric groups. Cross‐validation with the independent datasets NECS and the TAME consortium confirmed a robust aging signature, while fractional polynomial regressions revealed a specific ...
Flavien Delhaes +8 more
wiley +1 more source
Solution structure of the N-terminal dsRBD of Drosophila ADAR and interaction studies with RNA [PDF]
Adenosine deaminases that act on RNA (ADAR) catalyze adenosine to inosine (A-to-I) editing in double-stranded RNA (dsRNA) substrates. Inosine is read as guanosine by the translation machinery; therefore A-to-I editing events in coding sequences may ...
Barraud +59 more
core +4 more sources

